menu

Immune Landscape Signatures

Gene expression and analysis services for the detection of Immune Landscape Signatures attributable to 15 key immune cell subtypes, individual genes, and ratios

Interplay between various immune cell activities in human tumors contributes to patient responses to treatment with checkpoint inhibitors as well as overall patient outcomes. RNA expression analysis can be performed on Illumina RNA sequencing, NanoString or HTG EdgeSeq gene expression platforms using RNA or total nucleic acids isolated from FFPE or fresh frozen tumor specimens.

Results for the individual signatures are output as Immune Landscape Signature Scores, non-standardized and standardized across the project. The Immune Landscape Signature Scores can be used to determine immunogenic status of solid tumors. These signatures can also be used in a single- or multi-factor analysis of treatment response and survival, along with other clinicopathological and genomic co-factors such as tumor mutational burden.

Product Highlights
  • Detection of 15 Immune Landscape Signatures, characterizing key immune cell subtypes, pathways and individual genes, with potential predictive and prognostic utility across many cancer types (publication in progress).
  • Gene sets comprising individual Immune Landscape Signatures have been expertly developed across thousands of RNA expression tumor samples from various cancer indications to construct co-expression clusters attributed to specific immune cell subtypes.
  • All signatures show correlation with either event free survival (event, disease progression or death) or overall survival or both in multiple cancer types independent of the treatment type (publication in progress).
  • We offer streamlined analysis with flexibility to include novel genes or groups of genes of interest.
  • Available as an output from the following platforms:
    • Illumina RNA Access (preferred for FFPEs), Illumina TruSeq Stranded mRNA sequencing, Stranded Total Gold RNA sequencing
    • NanoString PanCancer Immune Profiling panel, NanoString PanCancer IO 360 panel
    • HTG EdgeSeq Immuno-Oncology panel, HTG EdgeSeq OBP panel
Product Deliverables
  • Immune Landscape Signature Score Card, standardized across project, per patient.
  • Platform-dependent raw data output files.
  • Custom statistical analysis for association with treatment response available.

Immune Landscape Signatures
Signature Description
1 Cytotoxic Lymphocyte Immune Signature Anti-tumor immune defense including CD8+ cytotoxic T cells, natural killer cells, and CD4+ effector T cells
2 CD8+ T cells Primary adaptive immunity killer cells (cytotoxic T lymphocytes, or CTL)
3 B cells Antigen presentation and antibody production
4 T cell Trafficking CXCR3 Ligands, T cell recruitment
5 M2 TAM macrophages Anti-inflammatory, tumor-promoting, and immune suppression activity
6 IFN-γ Key marker of general immune activity
7 TGF-β Marker of general immunosuppressive activity
8 Wound healing* Promotes angiogenesis
9 IFN-γ Response Stromal response to IFN-γ
10 TGF-β Response Stromal response to TGF-β (suppressive)
11 LAG3 Key marker of general immune activity
12 FOXP3 Key marker of regulatory CD4+ T cells
13 T cell Trafficking / M2 TAM ratio Recruitment vs. suppression of effector T cells. Useful outcome predictor in event-free and overall survival (publication in progress).
14 CD28/CTLA4 ratio T cell activation (CD28) / negative regulator (CTLA4) checkpoint
15 PD1/PDL1 ratio T cell de-activation checkpoint
* Not available for some focused panels